With Biotech (XBI) up 2.4%, this looks like a sector-led move rather than a company-specific surprise.
The biotech sector is trading significantly higher, driven by a series of positive industry-specific catalysts. Vir Biotechnology announced that its pivotal Phase 3 trial for a chronic hepatitis delta drug combination successfully met all of its endpoints. This positive clinical data boosts confidence in the sector's drug development pipeline. Adding to the positive sentiment, Argenx announced a definitive agreement to acquire Unnatural Products Inc. for a potential total of $1.15 billion, signaling robust M&A activity in the space.